Bioxytran Inc (BIXT) is a clinical-stage biopharmaceutical company developing therapeutic molecules for stroke, viral infection, and related hypoxic conditions. The company generates no product revenue as of the fiscal year ended December 31, 2025, funding operations entirely through private placements of common stock and convertible notes. Bioxytran's lead pipeline assets include BXT-25, an injectable acellular oxygen carrier designed to treat ischemic stroke by crossing the blood-brain barrier and diffusing oxygen into brain tissue, and ProLectin-M, a chewable polysaccharide tablet targeting mild to moderate SARS-CoV-2 infection via galectin inhibition. The company also holds investigational new drug authorizations from India's CDSCO for ProLectin-I and ProLectin-F, covering intravenous COVID-19 treatment and ventilator-induced lung fibrosis, respectively. Bioxytran is headquartered in Needham, Massachusetts, and operates a subsidiary, Pharmalectin India Pvt Ltd., which manages local clinical research and holds commercialization rights in India. The company carries an accumulated deficit and a stockholders' deficit as of December 31, 2025, and its platform technology is built on the galectin research of founder David Platt, PhD.

Revenue model

No product revenue is disclosed in the 10-K for fiscal years ended December 31, 2025 or December 31, 2024. Operations are financed through private placements of common stock, convertible notes, and affiliate loans. The company is pre-commercial and dependent on external capital to fund clinical development.

Products and services

BXT-25: injectable acellular oxygen carrier targeting ischemic stroke, designed to carry oxygen across the blood-brain barrier; animal testing reported successful as of April 19, 2023. ProLectin-M: chewable polysaccharide tablet for mild to moderate COVID-19, based on galectin inhibition of SARS-CoV-2 spike protein. ProLectin-I: IV formulation for hospitalized moderate COVID-19 and Long Covid patients; IND issued by India's CDSCO on January 27, 2023. ProLectin-F: treatment for ventilator-induced lung fibrosis; IND also issued January 27, 2023. ProLectin-A: earlier-stage antiviral candidate requiring approximately $12 million in additional funding to reach Phase II/a trials.

Customers and end markets

No commercial customers as of December 31, 2025. Target end markets are acute ischemic stroke treatment, SARS-CoV-2 infection and Long Covid, and ventilator-induced lung fibrosis. Clinical activity is concentrated in India through Pharmalectin India Pvt Ltd.

Value-chain role

Early-stage drug developer. The company discovers and develops therapeutic molecules internally, conducts animal and clinical trials, and intends to seek regulatory approval (FDA, CE mark from the European Directorate for the Quality of Medicines, CDSCO). Pharmalectin India Pvt Ltd. manages local clinical trials and holds India commercialization rights. No manufacturing or commercial sales infrastructure is disclosed.

Geographic exposure

Headquartered in Needham, Massachusetts. Clinical operations conducted in India through subsidiary Pharmalectin India Pvt Ltd. Regulatory filings reference FDA (United States) and the European Directorate for the Quality of Medicines for CE mark.

Source: SEC 10-K, filed 2026-04-15

Industry: Pharmaceutical Preparations Peers: Adverum Biotechnologies, Inc. Elutia Inc Checkpoint Therapeutics, Inc. CytomX Therapeutics Inc Climb Bio Inc Galectin Therapeutics Inc Q32 Bio Inc Immunic Inc vTv Therapeutics Inc